TRANSTHERA-B

02617
7.1301.79% ( -0.130 )
Delay Closed: Nov 17, 16:08:15

Profile

About

TRANSTHERA-B
TRANSTHERA-B
02617.HK

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc.

Profile

Company Name
TransThera Sciences (Nanjing), Inc.
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management